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Antiphospholipid syndrome (APS) is a chronic and disabling condition characterized
by recurrent thrombosis and miscarriages mediated by antibodies against
phospholipid-binding proteins (aPL), such as beta2glycoprotein I (β2GPI). Complement
is involved in APS animal models and complement deposits have been documented
in placenta and thrombotic vessels despite normal serum levels. Analysis of circulating
blood cells coated with C4d displays higher sensitivity than the conventional assays
that measure soluble native complement components and their unstable activation
products in systemic lupus erythematosus (SLE). As C4d-coated blood cell count has
been reported to be more sensitive than serum levels of complement components and
their activation products in systemic lupus erythematosus (SLE) patients, we decided
to evaluate the percentage of C4d positive B lymphocytes (BC4d), erythrocytes (EC4d),
and platelets (PC4d) in primary APS patients and asymptomatic aPL positive carriers
as marker of complement activation in APS. We assessed by flow cytometry the
percentages of BC4d, EC4d, and PC4d in primary APS (PAPS; n. 23), 8 asymptomatic
aPL positive carriers, 11 APS-associated SLE (SAPS), 17 aPL positive SLE, 16
aPL negative SLE, 8 aPL negative patients with previous thrombosis, 11 immune
thrombocytopenia (ITP) patients, and 26 healthy subjects. In addition, we used an
in vitro model to evaluate the ability of a monoclonal anti-β2GPI antibody (MBB2) to
bind to normal resting or activated platelets and fix complement. EC4d and PC4d
percentages were significantly higher in PAPS and aPL carriers as well as aPL positive
SLE and SAPS than in aPL negative controls. The highest values were found in PAPS
and in SAPS. The EC4d and PC4d percentages were significantly correlated with serum
C3/C4 and anti-β2GPI/anti-cardiolipin IgG. In vitro studies showed that MBB2 bound
to activated platelets only and induced C4d deposition. The detection of the activation
product C4d on circulating erythrocytes and platelets supports the role of complement
activation in APS. Complement may represent a new therapeutic target for better
treatment and prevention of disability of APS patients.
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INTRODUCTION
Antiphospholipid syndrome (APS) is a chronic
autoimmune disease characterized by recurrent thrombotic
events and pregnancy morbidity, in the presence of antibodies
targeting anti-phospholipid binding proteins (aPL) (1). APS can
be found in patients with no evidence of associated diseases
(primary APS, PAPS) or with other autoimmune disorders,
mainly systemic lupus erythematosus (SLE) (SAPS) (1).
The major aPL antigenic target is β2-glycoprotein I (β2GPI),
a phospholipid binding plasma protein of 50 kDa (2). Upon
binding to anionic phospholipids or to membrane receptors
of different cell types, β2GPI changes conformation, exposing
an immunodominant cryptic epitope located at domain I
(D1), which is recognized by aPL. There is sound evidence
from in vitro and in vivo models that β2GPI-dependent aPL
play a pathogenic role both in thrombosis and pregnancy
complications (3, 4). Moreover, epidemiological data support a
strong diagnostic/prognostic value of anti-D1 antibodies in APS
patients (5).
Complement activation was initially suggested to be involved
in APS animal models since the induction of fetal loss or
thrombosis by passive infusion of aPL IgG was prevented
by treatment with inhibitors of complement activation or
the use of animals deficient in complement components (6–
10). Moreover, a human monoclonal antibody against β2GPI
D1 lacking the complement-fixing portion of the molecule
(MBB21CH2), unlike the complement-fixing parent molecule
(MBB2) that reacts with the same epitope (11) fails to exhibit
pathogenic effect. In contrast, low C3 and C4 serum levels were
described in some APS patients only and few studies reported
high levels of complement activation products (fragment Bb and
anaphylatoxins C4a, C3a, and C5a) with no association with the
vascular manifestations of the syndrome (12–15). On the other
hand, we recently reported deposition of C1q, C4, C3, and C9
on the endothelium of the vessel wall close to the thrombotic
occlusion in a PAPS patient who underwent bypass surgery
to treat an arterial thrombotic occlusion. Notably, complement
components co-localized with β2GPI and IgG, suggesting that
aPL caused complement activation and contributed to the
pathogenesis of the thrombotic event (16).
Measurement of serum levels of complement activation
products has been reported to be more sensitive than that of
native complement components in SLE (17). In particular, the
number of C4d-coated B lymphocytes, erythrocytes and platelets
in circulating blood of SLE patients with active disease was higher
than in controls (17–24).
The number of C4d-bound platelets was associated with lupus
disease activity and complement consumption but contrasting
results regarding the association with arterial or venous events
and aPL were reported (25, 26). This finding is in contrast with
the ability of aPL to activate complement and promote binding of
complement split products to fixed platelets in vitro (25, 27, 28).
We have investigated the percentage of C4d positive
circulating blood cells in PAPS and report a higher number of
C4d positive erythrocytes and platelets in aPL positive patients
than in controls supporting the hypothesis that complement is
activated in vivo. Amechanistic model of complement deposition
on platelets in the presence of a human monoclonal antibody
specific for D1 of β2GPI was investigated as well.
MATERIALS AND METHODS
Patients and Controls
We recruited the following patients: 23 PAPS; 11 SAPS, 17
aPL positive SLE, and 16 aPL negative SLE. As controls we
included: 11 patients with primary immune thrombocytopenia
(ITP), 8 aPL negative patients with previous thrombotic episodes,
8 persistently positive aPL healthy subjects (aPL positive
carriers), and 26 normal healthy subjects (NHS). SLE patients
were classified according to the 1997 American College of
Rheumatology updated criteria for SLE and the new 2012
SLICC SLE criteria (29, 30). Disease activity in SLE patients
was assessed by the SELENA version of SLEDAI index in SLE
(31). APS patients fulfilled the revised Sapporo criteria (32). The
characterization of vascular and obstetric APS was carried out as
previously reported (33). Primary ITP was diagnosed according
to the International Working Group criteria (34).
All ITP patients were in stable clinical remission. Anti-
phospholipid negative patients with thrombosis had previous
documented episodes of myocardial infarction, stroke, transient
ischemic attack, pulmonary embolism, or deep vein thrombosis.
When entering the protocol, all subjects underwent a
detailed clinical evaluation and comprehensive medical history
registration. Recorded variables included sex, age, disease
duration and therapy (Supplementary Table 1). To avoid any
modification due to the acute phase reactants, samples have been
collected at least six months after the thrombotic event (35). The
protocol was approved by the local Institutional Review Board
(IRB) (Comitato Etico Milano area 2–426_2014) and all subjects
gave written informed consent.
Blood Samples
Venous blood samples were collected from an antecubital vein
using a 21-gauge butterfly needle with minimal stasis. The first
3mL were collected into K2E EDTA tubes (Becton Dickinson
vacutainer, North Ryde, NSW, Australia) and analyzed by coulter
hematology analyser for blood cell count (DxH-800, Beckman
Coulter, Milano, Italy). Additional blood samples included:
3mL in K2E EDTA for measurement of C4d deposition on B
lymphocytes, red blood cells and platelets by flow cytometry;
3mL in CTAD vacutainer for lupus anticoagulant (LAC)
determination; 5mL in vacutainer without anticoagulant for
serum collection. Five mL of blood were collected into desirudin
(Revasc, 25µg/mL) and used for experiments of C4d deposition
on in vitro stimulated and resting platelets.
Serum Complement Determination
Serum concentrations of complement components C3 and
C4 were determined by an immunoturbidimetric method
(Roche/Hitachi cobas c 701/702): C3 and C4 normal ranges
indicated by the manufacturer were 55–180 and 20–50
mg/dL, respectively.
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Detection of aPL
Serum anticardiolipin (anti-CL) and anti-β2GPI IgG/IgM
autoantibodies were detected as previously described (36). LAC
was measured according to international ISTH guidelines (37).
Detection of C4d Bound to Cells by Flow
Cytometry
The percentage of C4d bound to B lymphocytes (BC4d),
erythrocytes (EC4d), and platelets (PC4d) was measured by flow
cytometry after subtraction of background signals. All analyses
were performed using a FACS Calibur cytometer and Cell Quest
software (BD Biosciences, San Jose, CA). In all experiments,
control procedures to establish proper calibration, compensation,
and linearity were performed.
C4d Bound to B-Lymphocytes
Erythrocytes lysis was performed by addition of ammonium
chloride–based reagent (BD Pharm Lyse; BD Biosciences, San
Jose, CA) to EDTA-whole blood (300 µL), left 10min at 4◦C and
centrifuged at 800 g at 4◦C for 5min. Cell pellet was suspended
in 1mL of Dulbecco’s phosphate buffered saline (DPBS, Sigma-
Aldrich, St. Louis, MO) supplemented with 1% heat-inactivated
fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, MO) (DPBS/1%
FCS) and stained at 2–8◦C with 10µg/mL purified mouse
monoclonal antibodies against human C4d (mouse anti-human
C4d; Quidel, San Diego, CA) or 10µg/mL mouse anti-human
isotype control IgG1κ (MOPC-21; BD Biosciences, San Jose, CA)
for 45min. Samples were then washed with DPBS/1%FCS and
centrifuged at 800 g at 4◦C for 5min. Pellets were suspended in
a DPBS/1%FCS solution containing fluorescein isothiocyanate
(FITC) conjugated goat anti-mouse antibody (Cappel, MP
biomedicals, Santa Ana, CA) (10µg/mL) and R-phycoerythrin
(PE)-conjugated monoclonal antibody against human CD-19
(a 95-Kd type I transmembrane glycoprotein expressed on
B cells) (BD Biosciences, San Jose, CA), and stained at 2–
8◦C in the dark for 45min. Samples were washed again and
suspended in 250 µL cold DPBS/1%FCS. 5,000 events in the
lymphocytes gate (based on their size) were acquired at high
flow rate. A single fluorochrome dot plot strategy was used to
identify B-lymphocytes CD19 positive (SSC vs. CD19-PE) and
the percentage of C4d was assessed on B-lymphocytes gate (SSC
vs. FITC).
C4d Bound to Erythrocytes
EDTA-whole blood (50 µL) was suspended in 1,5mL
DPBS/1%FCS and centrifuged for 5min at 800 g at 4◦C.
The pellet was suspended in 500 µL DPBS/1%FCS; 10 µL of the
suspension was subsequently stained with anti-C4d monoclonal
antibody or mouse anti-human isotype control IgG1κ at 2–8◦C
for 45min. Samples were then washed and cell surface C4d
was detected by addition of FITC-conjugated goat anti-mouse
antibody at 2–8◦C in the dark for 45min. Samples were washed
again and suspended in 250 µL of cold DPBS/1%FCS. 5,000
events in the erythrocytes gate were acquired with a high flow
rate. A single fluorochrome dot plot strategy (FSC vs. FITC) was
used for quantification of percentage of C4d on erythrocytes.
Details regarding the erythrocyte gating strategy are shown in
Supplementary Figure 1.
C4d Bound to Resting Platelets
EDTA-whole blood samples (50 µL) were diluted with
DPBS/1%FCS (1:2) and stained with anti-C4d monoclonal
antibody or mouse anti-human isotype control IgG1κ at 2–8◦C
for 45min, followed by staining with FITC-conjugated goat
anti-mouse antibody at 2–8◦C in the dark for 45min. A PE–
conjugated monoclonal antibody against human CD42b (a 145
kD glycoprotein known as GPIbα) was used to identify platelets.
5,000 events in the platelet gate were acquired at low flow rate. A
single fluorochrome dot plot strategy was used to identify CD42b
positive platelets (SSC vs. CD42b-PE) and the percentage of
C4d was measured (SSC vs. FITC). Details regarding the platelet
gating strategy are shown in Supplementary Figure 2.
MBB2 Antibody
The human monoclonal antibody against D1 of β2GPI
(MBB2) has been produced and characterized as previously
published (11).
In vitro Model of C4d Binding to
Normal Platelets
Hirudin-anticoagulated whole blood from healthy blood donors
was diluted in home-made PBS (1:15) and incubated with
or without 500µg/mL of MBB2 and/or thrombin receptor
activating peptide (TRAP, Sigma-Aldrich, Germany) (20µM) at
37◦C for 20min. Samples were then diluted with PBS (1:10)
and stained with 10µg/mL mouse anti-human C4d or 10µg/mL
mouse anti-human isotype control IgG1κ at RT for 20min.
Then, FITC-conjugated goat anti-human antibody (Cappel, MP
biomedicals, Santa Ana, CA) and/or APC-conjugated goat anti-
mouse antibody (ThermoFisher scientific Massachusetts, USA),
and/or anti-CD42b-PE, and/or anti-CD62p-Pe/Cy7 (Biolegend,
San Diego, CA) were added to the samples and incubated at RT in
the dark for 20min. After incubation, samples were diluted in 300
µL PBS and immediately analyzed by flow cytometry. All analyses
were performed using a FACS Verse cytometer and FACS Suite
software (BD Biosciences, San Jose, CA). 5,000 events in the
platelet gate were acquired with a medium flow rate. Dot plot
strategy was used for analysis: first of all, platelets were identified
with CD42b-PE vs. SSC, then C4d-APC or MBB2-FITC or
CD62p-Pe/Cy7 vs. SSC were used to determine the percentage
of C4d and MBB2 platelet bound and of CD62p expression.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
6.0 (GraphPad Software Inc., San Diego, CA, USA). All
results were expressed as median with interquartile range. The
normality of data was evaluated by the D’Agostino-Pearson test.
Comparisons between groups were performed using Kruskal-
Wallis or Friedman tests as appropriate followed by Dunn’s post-
hoc test. Comparison between two groups were performed using
Wilcoxon t-test. All tests were two tailed. Correlations between
variables were expressed as Spearman’s correlation coefficient.
p< 0.05 was chosen as the cut-off level for statistical significance.
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RESULTS
aPL Profile of Patients and Controls
Normal healthy subjects and pathological controls (ITP, SLE,
and patients with previous thrombosis) were negative in all aPL
assays. Among the 17 aPL positive SLE patients, three displayed
single, 7 double and 7 triple positivity. Four out of 11 SAPS
patients were single-positive, 1 double-positive and 6 triple-
positive for aPL; 4/8 aPL positive carriers were double- and 4/8
triple-positive; of the 23 PAPS patients, 1 was single-, 5 double-,
and 17 triple-positive.
C3 and C4 Serum Levels
aPL positive carriers and PAPS patients displayed lower serum
levels of C3 and C4 than normal healthy subjects, albeit their
values fell in the normal range (Table 1).
Measurement of Cell-Bound C4d
Significantly higher percentages of both EC4d and PC4d were
found in aPL positive SLE, SAPS and PAPS patients compared
to NHS, ITP patients, and aPL negative thrombotic patients;
moreover, higher percentages of EC4d and PC4d were detected
also in aPL negative SLE and asymptomatic healthy aPL positive
carriers (Figures 1A,B). Patients with SLE with or without aPL or
full blown APS displayed higher BC4d percentages than PAPS or
aPL positive carriers. On the contrary, the percentages of BC4d
in aPL positive carriers and PAPS were comparable with the
controls (Supplementary Figure 3).
Cell-bound C4d percentages were comparable both in
thrombotic and obstetric APS patients, suggesting that they were
not associated with the main APS clinical manifestations
(Supplementary Figure 4); moreover, we did not find
any correlation also with non-classification criteria (e.g.,
thrombocytopenia; Supplementary Figures 5–7) (32).
Correlations Between the Percentage of
PC4d and EC4d With Other
Laboratory Parameters
C4 Serum levels were found to be inversely correlated with the
percentage of PC4d (r = −0.4682, p < 0.0001; Figure 2A) and
EC4d (r =−0.5163, p< 0.0001; Figure 2B).
There was a positive correlation of both anti-β2GPI IgG (r
= 0.2486, p = 0.0157) and anti-CL IgG (r = 0.4537, p <
0.0001) titers with PC4d (Figures 3A,B). The correlation between
PC4d and anti-CL IgM was mild, but statistically significant (r
= 0.2472, p = 0.0163; Supplementary Figure 8B). In contrast,
there was no correlation between PC4d and anti-β2GPI IgM
titers (r = 0.09486, p = 0.3631) (Supplementary Figure 8A).
EC4d percentages positively correlated with anti-β2GPI IgG
(r = 0.3503, p = 0.0005) and anti-CL IgG (r = 0.4805, p
< 0.0001) (Supplementary Figures 9A,B). There was also a
positive correlation between EC4d and both anti-β2GPI IgM (r
= 0.2672, p = 0.0092) and anti-CL IgM (r = 0.4177, p < 0.0001)
(Supplementary Figures 9C,D).
In vitro Studies: MBB2 and C4d Deposition
on Resting and Activated Platelets
Since β2GPI-dependent aPL may recognize β2GPI adhered
on activated platelets (3), we set up an in vitro model to
investigate whether the bound antibody was responsible for
cell membrane deposition of C4d. To this end, hirudin-
anticoagulated whole blood samples from NHS (n = 11) were
incubated with TRAP, a platelet agonist. In the absence of
exogenous stimuli, the expression of CD62p on platelets was
negligible, while it dramatically increased after addition of TRAP.
These results indicate that circulating NHS platelets were not
activated, offering a suitable in vitro model to investigate the
possible role of platelet activation in β2GPI adhesion to cell
membranes and antibody binding (Figure 4A). Blood samples,
which provided the source of resting platelets, autologous β2GPI
and complement, were incubated with MBB2. The binding of
MBB2 to resting platelets was negligible (0.4%) but it increased
up to 18 times (7.5%; p = 0.002) following platelet stimulation
by TRAP (Figure 4B). This finding suggests that pathogenic
aPL may recognize autologous β2GPI bound only to activated
platelets. We then investigated whether the bound antibody
was able to activate complement and to induce C4d deposition
on the platelet membranes. The percentages of PC4d increased
significantly when the blood samples were simultaneously
incubated with TRAP and MBB2, suggesting that MBB2 reacted
with adhered β2GPI and activated complement, leading to C4d
deposition on activated platelets (Figure 4C).
DISCUSSION
Complement has been shown to be activated in several systemic
autoimmune diseases and plays a key role in SLE and in
SLE-related disorders (38). Although there is ample evidence
that thrombosis and fetal loss are complement dependent in
experimental models of APS, complement activation in APS
patients is still matter of debate (15). Our results show for the
first time increased percentages of C4d complement activation
product that is stably deposited on cell membranes of platelets
and erythrocytes in PAPS.
High percentages of platelet C4d were reported to be
specific for SLE (17–24). We confirmed this finding in
aPL negative SLE patients included in this study as a
pathological control group. The percentages of C4d bound to
circulating blood cells, in particular to platelets, display higher
sensitivity than the conventional assays that measure soluble
complement components and their unstable activation products.
Consequently, platelet C4d percentages have been suggested as
useful and sensitive tool for mirroring complement activation in
SLE patients (17).
The finding of increased percentages of PC4d and EC4d in
PAPS and in aPL positive carriers but not in healthy controls
and patients with ITP strongly suggests that the presence of
aPL is specifically associated with in vivo complement activation.
Comparable percentages were found in aPL negative and aPL
positive SLE patients with no APS clinical manifestations
supporting the hypothesis that SLE and the presence of aPL may
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TABLE 1 | Serum levels of C3 and C4.
NHS
(n = 26)
ITP
(n = 11)
aPL neg
thrombosis
(n = 8)
aPL neg SLE
(n = 16)
aPL pos SLE
(n = 17)
SAPS
(n = 11)
aPL pos
carriers
(n = 8)
PAPS
(n = 23)
C3 (mg/dL)
(normal range: 55–180
mg/dL)
129 ± 9 124 ± 11 159 ± 11 92 ± 6 76 ± 5 73 ± 7 97 ± 11 89 ± 4
C4 (mg/dL)
(normal range: 20–50
mg/dL)
31 ± 3 25 ± 3 34 ± 4 19 ± 3 10 ± 1 15 ± 4 20 ± 2 20 ± 2
NHS, normal healthy subjects; ITP, primary immune thrombocytopenia; aPL, anti-phospholipid antibodies; SLE, systemic lupus erythematosus; SAPS, secondary antiphospholipid
syndrome; PAPS, primary antiphospholipid syndrome.
Values are reported as mean ± SEM.
FIGURE 1 | C4d deposition on platelets and erythrocytes. Flow cytometry was performed on EDTA-whole blood samples (n = 120). C4d-positive cells were detected
by purified anti-human C4d and FITC conjugated goat anti-mouse antibody on platelets (A) and on erythrocytes (B). Results are expressed as percentage, median
with interquartile range, and analyzed by Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test. *p < 0.05; **p < 0.01, ***p < 0.001 vs. NHS.
FIGURE 2 | Correlations between C4 serum levels and EC4d and PC4d percentages. C4 serum levels (mg/dL) negatively correlated with the percentages of PC4d
(A) and EC4d (B).
be independently linked to complement activation. On the other
hand, full blown APS was associated with the highest EC4d and
PC4d percentages both in PAPS and in SLE-associated APS. Since
themajority of these patients had a history of vascular thrombotic
events, we investigated whether a previous thrombosis may affect
the percentages of C4d positive cells in the absence of aPL. This
possibility was ruled out by the observation that the control group
of aPL negative thrombotic patients had normal percentages
of C4d positive cells further supporting the specificity of this
parameter for in vivo complement activation in APS.
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FIGURE 3 | Correlations between anti-β2GPI and anti-CL IgG titers PC4d. PC4d titers positively correlated with both IgG anti-β2GPI (A) and IgG β2GPI-dependent
anti-CL titers (B).
FIGURE 4 | Effects of MBB2 and TRAP, alone and in combination, on the expression of CD62p on platelets. Percentages of CD62p-, MBB2-, and C4d-positive
platelets were measured in hirudin-anticoagulated blood from 11 NHS after its incubation with or without MBB2 and/or TRAP at 37◦C for 20min. Data were analyzed
by Friedman test and Dunn’s multiple comparisons post-hoc test (A,C) and by Wilcoxon matched paired test (B). Results are expressed as percentage, median with
interquartile range. *p < 0.05; **p < 0.01, ***p < 0.001 vs. MBB2.
Although the serum levels of C3 and C4 in PAPS and in
aPL positive carriers were reduced in comparison with healthy
controls and patients with ITP or previous thrombosis without
aPL, they were still within the normal range. Moreover, C4d
positive cells significantly correlated with both serum C3 and
C4 values and titers of anti-β2GPI and β2GPI-dependent anti-
CL IgG. These findings are consistent with the hypothesis
that the presence of aPL is associated with complement
activation in APS.
Few recent studies reported reduced complement levels and
increased levels of activation products in someAPS patients albeit
without clear association with the clinical manifestations of the
syndrome (12–14). The high percentages of both EC4d and PC4d
in our study further support the involvement of complement in
APS. The lack of association with the clinical manifestations of
the syndrome was confirmed in our study in spite of the use
of a more sensitive and reliable laboratory tool for detection of
complement activation.
Complement activation in APS patients should be associated
with complement deposition in damaged tissues. There is
sound evidence that this is the case for placenta both in
animals and in patients (15). A role of complement for the
aPL-mediated placenta damage has been suggested in animals
while it is still matter of research in humans (15). On the
other hand, although less studies looked at vessel complement
deposition, the available data are suggestive for a role of
complement in endothelial perturbation that may be pivotal for
the thrombophilic state (16, 39).
Both circulating and tissue immune complexes are known
to play a critical role in activating the complement cascade
in SLE (38). Their deposition on the membrane of circulating
blood cells explains the increased percentages of C4d positive
cells; however additional pathways have been suggested to
mediate the binding of complement components to activated
platelets without the need of immune complex formation (40).
In contrast, the mechanism(s) responsible for complement
activation in APS has not been clarified yet. Although circulating
anti-β2GPI/β2GPI complexes can be found in a limited
proportion of patients (41, 42), they are undetectable in most
of them suggesting that tissue bound complexes (e.g., on vessel
walls) (16, 39) and/or additional mechanisms play a role in
complement activation.
Beta2GPI is the main target for diagnostic and pathogenic
aPL and it is general accepted that binds to activated platelets
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through several candidate membrane receptors or just because of
the electrostatic interaction between the cationic PL-binding site
of β2GPI and the anionic phospholipid (i.e., phosphatidylserine)
that is exposed in the outer cell membrane leaflet upon
cell activation (3). Once bound, the adhered β2GPI exposes
the immunodominant epitope on D1 that is recognized by
pathogenic aPL that in turn may activate complement (3). With
this in mind, we set up an in vitro model in which normal
platelets were incubated with anti-D1 monoclonal antibody in
the presence or absence of a platelet agonist (i.e., TRAP) and
autologous serum as a source of β2GPI and complement. Our
in vitro results support only in part the role of immune complexes
for complement deposition on the platelet cell membrane,
because only a small percentage of activated platelets actually
displayed membrane C4d. Additional mechanisms that do not
require immune complex formation at the platelet surface may
play a role as also suggested in SLE patients (40). Moreover,
we can speculate that abnormalities in PAPS or SLE platelets
themselves may be responsible for the increased complement
deposition on their surface.
In conclusion the detection of complement activation
products on circulating erythrocytes and platelets using a highly
sensitive and specific assay further supports the view that APS
is a complement-mediated disorder. Increased EC4d and PC4d
percentages are associated with the active inflammatory disease
in SLE. It is difficult to translate this finding to APS which
is a non-acute inflammatory disorder. We failed to find an
association with both the classification and non-classification
criteria, including thrombocytopenia. However, we believe that
this sensitive tool to evaluate complement activation may offer
more information in monitoring the dynamics of the aPL-
mediated pathogenic pathways during pregnancy rather than in
patients far from the acute thrombotic events.
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